Halozyme Therapeutics (HALO) announced that the commercial launch of Herceptin SC in Europe has triggered a $10M milestone payment to Halozyme under the License and Collaboration Agreement between Halozyme and Roche (RRHBY). This time-saving subcutaneous formulation of Herceptin using Halozyme's recombinant human hyaluronidase received marketing authorization from the European Commission on August 28 for the treatment of patients with HER2-positive breast cancer and was launched upon approval. Herceptin SC reduces treatment times and enhances convenience compared to the standard intravenous form.
- Health Care Industry
- Halozyme Therapeutics